期刊文献+

延长哌拉西林/他唑巴坦输注时间治疗复杂性尿路感染的临床观察 被引量:5

Clinical Observation of Extending Prolonged Infusion Time of Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections
原文传递
导出
摘要 目的:评价延长哌拉西林/他唑巴坦(PIP/TAZ)输注时间治疗复杂性尿路感染的疗效及安全性。方法:将我院于2012年10月-2014年10月收治的84例复杂性尿路感染患者按SPSS 15.0软件随机分组程序分为试验组和对照组各42例。试验组予以PIP/TAZ 4.5 g持续静脉泵入,q8 h,静脉泵入时间为3 h;对照组予以PIP/TAZ 4.5 g静脉滴注,q8 h,静脉滴注时间为30 min。两组均以7 d为1个疗程,观察实验室检查指标、降钙素原与血白细胞计数。结果:两组患者治疗后降钙素原均较治疗前明显下降,差异有统计学意义(P<0.05);且治疗后组间比较差异亦有统计学意义(P<0.05)。两组患者治疗后血白细胞计数均较治疗前明显下降,差异有统计学意义(P<0.05);但组间比较差异无统计学意义(P>0.05)。试验组的临床总有效率为85.4%,对照组的临床总有效率为63.4%,差异有统计学意义(P<0.05)。两组不良反应发生率均为2.4%,差异无统计学意义(P>0.05)。结论:延长PIP/TAZ输注时间治疗复杂性尿路感染疗效确切、安全性高。 OBJECTIVE: To evaluate the efficacy and safety of prolonged administration time of piperacillin/tazobactam (PIP/ TAZ) in the treatment of complicated urinary tract infections. METHODS: 84 patients with complicated urinary tract infections in our hospital from Oct. 2012 to Oct. 2014 were randomly divided into test group (n=42) and control group (n=42) by SPSS 15.0 software randomized program. The test group was given PIP/TAZ 4.5 g for 3 h, continuous iv,q8 h; control group was giv- en PIP/TAZ 4.5 g for 30 min, continuous iv, q8 h. The course was 7 d. The laboratory parameters, procalcitonin and white blood cell count were observed. RESULTS: After treatment, the procalcitonin in 2 groups were significantly decreased, with significant difference (P〈0.05) ; there was significant difference between 2 groups (P〈0.05). Compared with before, the white blood cell count in 2 groups were significantly decreased, with significant difference (P〈0.05); however, there was no significant differ- ence between 2 groups (P〉0.05). The total effective rat of test group was 85.4% and it of control group was 63.4%, with signif- icant difference (P〈0.05). The incidence of adverse reactions in 2 groups was 2.4%, with no significant difference (P〉0.05). CONCLUSIONS : Prolonged PIP/TAZ administration time has accurate efficacy and highly safety in the treatment of complicated urinary tract infections.
出处 《中国药房》 CAS 北大核心 2015年第14期1965-1967,共3页 China Pharmacy
基金 湖北民族学院博士启动基金资助项目(No.MY2014B020)
关键词 哌拉西林/他唑巴坦 复杂性尿路感染 输注时间 Piperacillin/tazobactam Complicated urinary tract infections Prolonged infusion time
  • 相关文献

参考文献13

  • 1陈岐辉,柳宏林,王晓庆,卢绩.哌拉西林/他唑巴坦治疗泌尿系感染210例临床分析[J].中华医院感染学杂志,2012,22(13):2905-2907. 被引量:9
  • 2马登扬,陈挺,蒋悦,吴晓芬,朱庆峰.哌拉西林/他唑巴坦治疗住院患者泌尿系统感染的疗效分析[J].中华医院感染学杂志,2013,23(7):1684-1685. 被引量:3
  • 3..抗茵药物临床应用指导原则[S]..卫生部,国家中医药管理局,总后卫生部,,2004-8..19..
  • 4杨启文,王辉,徐英春,陈民钧,苏丹虹,胡志东,廖康,曾吉,王勇,曹彬,褚云卓,张嵘,刘文恩,周春妹,宁永忠,徐修礼,卓超,田彬,陈冬梅,熊艳,李平,刘颖梅,年华,李丽红,邹明祥,谢红梅,杨佩红,孙宏莉,谢秀丽.2009年中国13家教学医院院内感染病原菌的抗生素耐药性监测[J].中华检验医学杂志,2011,34(5):422-430. 被引量:85
  • 5周晨霞,张瑞忠,陆志军,王志忠,徐振亚.尿路感染患者病原菌分布及耐药趋势分析[J].中国药房,2008,19(8):586-588. 被引量:12
  • 6尹明,沈洪.治疗细菌感染的新思路[J].中国危重病急救医学,2012,24(3):132-134. 被引量:9
  • 7Vall6s J, Rello J, Ochagavia A, et al. Community-acquired bloodstream infection in critically ill adult patients: im- pact of shock and inappropriate antibiotic therapy on sur- vival[J]. Chest,2003,123(5) : 1 615.
  • 8Page MG. Extended-spectrum beta-lactamases: structure and kinetic mechanism[J]. Clin Microbiol Infect, 2008, 14 (Suppl 1 ) : 63.
  • 9Kim A, Sutherland CA, Kuti JL, et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? [J]. Pharmacotherapy, 2007,27( 11 ) : 1 490.
  • 10Shea KM, Cheatham SC, Wack MF, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/ tazobactam administered by prolonged infusion in hospi- talised patients[J]. Int JAntimicrob Agents, 2009,34 (5) : 429.

二级参考文献79

共引文献133

同被引文献32

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部